New hope for advanced colon cancer: drug combo trial launches
NCT ID NCT07042685
First seen Jan 04, 2026 · Last updated May 07, 2026 · Updated 20 times
Summary
This study tests a new combination of chemotherapy (5FU-based) plus the targeted drug fruquintinib as the very first treatment for people with advanced colorectal cancer that cannot be removed by surgery or has spread. About 50 participants will receive the treatment in cycles, and if it works well after six months, they will continue on a lower maintenance dose. The goal is to see if this combo can delay cancer growth longer than current options, while monitoring side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER (CRC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Houston Methodist Neal Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.